RUTHERFORD, N.J., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, announced that new data that further validates its UroGenRA™-Kidney diagnostic test for renal cell cancer will be presented at the annual United States & Canadian Academy of Pathology (USCAP) meeting on March 3rd in San Diego, CA. The new data was generated as part of a collaborative study conducted with the Cleveland Clinic in which 191 pathology specimens from renal cancer patients were provided and analyzed using the UroGenRA™-Kidney test.
Help employers find you! Check out all the jobs and post your resume.
